COVID-19 Oral Antivirals for Pharmacist Only Supply

On July 14th 2022, the Associate Health Minister announced that Nirmatrelvir with Ritonavir (Paxlovid™) and Molnupiravir (Lagevrio®) were reclassified from prescription-only medicine to pharmacist-only (restricted) medicine.

The aim of this change is to increase timely access by allowing pharmacists to provide these oral antiviral medicines without a prescription to people who have COVID-19 and who meet the eligibility criteria set by PHARMAC. 

PSNZ has developed a training programme for pharmacists (and other health professionals). The programme will give you the tools needed to appropriately supply these medicines to our most vulnerable patients.

Register for the training now